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Abstract: The synthesis of five new analogues of benzopsoralens, derived from 
xanthen-9-one and carbazole is described. The preparation of the hydroxylated 
precursors, their formylation and the formation of the pyranone ring, by the 
reaction between ortho-formylated heterocycles and diethyl malonate in EtOH, 
will be discussed. The inhibitory effect on the growth of human tumour cell lines 
(MCF-7, SF-268 and NCI-460) of the final products was evaluated and is 
discussed in terms of the 3D-geometry and electronic density distribution. The 
compounds showing significant biological activity in this study were those having 
angular structures. 
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1. Introduction.- Psoralens are natural products derived from coumarin. Some of 
their derivatives are photosensitising drugs and are used for treatment of various 
skin diseases (e.g. cutaneous malignant melanoma) [1], blood decontamination, 
and some AIDS related infections [2]. In a previous publication, our research 
group prepared psoralen analogues (e.g. 1) based on dibenzofuran [3] and studied 
their properties. Some of them showed sensitization of singlet oxygen with high 
quantum efficiency [4] and good ability to inhibit the in vitro growth of three 
human tumour cell lines representing different tumour types, MCF-7 (breast 
cancer), NCI-H460 (non-small cell lung cancer) and SF-268 (CNS cancer) [5].  
In view of the antitumour properties referred above for compounds of type 1, it 
was decided to evaluate the effects on the biological properties of modifications 
on the furan ring. The first modification consisted on the replacement of the 
oxygen atom by NH giving 2 and 3,  isosters of  oxopyranodibenzofuran (1). The 
replacement of the furan ring by 1,4-pyranone gave xanthone derivatives, 4, 5 and 
6, close analogues of  xanthonolignoids studied previously by members of our 
group [6]. 
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The five tetracyclic compounds which were synthesized were tested for their 
growth inhibitory activity against three human tumor cell lines. 
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2. Results and discussion.- 2.1. Chemistry. In order to build the pyranone ring by 
the same method that was used before [3], ortho-hydroxyaldehydes compounds, 
were needed as starting materials. 
The hydroxylated xanthen-9-ones 7 were prepared by known procedures [7] and 
were then formylated, to give products 8, by different methods.  
The first attempt to formylate the hydroxylated xanthones 7 used the Duff reaction 
[7, 8]. By this method, hydroxyaldehydes 8b, 8c, 8d, and 8a  were obtained in 56, 
32, 17, and 13% yields, respectively (Scheme 1). The Reimer-Tiemann 
formylation [9] gave compound 8a in an even lower yield (6%). In the 1H-NMR 
spectra of all the hydroxyaldehydes 8, a low field signal was observed 
corresponding to the H-bonded OH, and the lowest signal of all (δ = 13.54 ppm) 
corresponded to compound 8a.  
INSERT SCHEME 1 
The pyranone ring was built from ortho-formylhydroxyxanthen-9-ones 8b-8c, by 
reflux with diethyl malonate in EtOH in the presence of AcOH and pyridine [10] 
(Scheme 2) and compounds 4 and 5 were obtained in 50 and 55% yields, 
respectively. In the 1H-NMR spectra, the signals of the hydroxyl and aldehyde 
groups were replaced by a low field singlet, corresponding to H-1 of the pyranone 
ring. It is interesting to point out that the low field singlet for compound 4 appears 
at δ 10.57 and for compound 5 at 9.21 ppm. As a consequence of the low yields  
of the formylation of hydroxyxanthenones 7a and 7d, the preparation of the 
corresponding oxopyrano-xanthenones, was not accomplished. 
 
INSERT SCHEME 2 
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For the synthesis of pyranoxanthen-9-one 6, another approach was used. 3-
Methoxyxanthen-9-one was reduced [11] to the 3-methoxyxanthene (77%, 
LiAlH4)  (Scheme 3). 
Vilsmeier formylation [12] (POCl3 and N-methylformanilide) gave the aldehyde 
9a in 31% yield, which was demethylated quantitatively, using BBr3 [13], to give 
the aldehyde 9b (Scheme 3). 
The usual method was applied for the construction of the pyranone ring, reacting 
9b with diethyl malonate, and xanthene 10 was obtained in high yield (73%). 
Oxidation of 10 by chromium (VI) oxide [7a] gave 6 in 83% yield (Scheme 3).  
INSERT SCHEME 3 
Aldehydes 11b and 11c were obtained from commercial 2-hydroxycarbazole. The 
Reimer-Tiemann formylation gave 11b in 20% yield [14] (Scheme 4), whereas 
11c was prepared in 32% by subsequent metalation  and treatment with DMF [16] 
from the carbamate 11a, which was obtained in good yield (c.f. [15]). 
INSERT SCHEME 4 
The ortho-formylhydroxycarbazoles 11b and 11c were then converted to the 
oxopyranocarbazoles 2 and 3, in 17 and 27% yield, respectively, following the 
usual method [10]. 
The structures of the final products were confirmed by mass spectrometry, IR and 
NMR spectroscopy.  
2.2. Biological activity - Effect of compounds on the growth of human tumour cell 
lines 
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The ability of oxopyranoxanthenones 4, 5 and 6 and the oxopyranocarbazoles 2 
and 3 to inhibit the in vitro growth of MCF-7, NCI-H460 and SF-268 cell lines 
was evaluated and the results, given in concentrations that were able to cause 50% 
of cell growth inhibition (GI50), are summarized in Table 1. 
Among the compounds tested the angular pyranocarbazole 2 was found to have 
the best inhibitory activity against all the three cell lines, while pyranocarbazole 3, 
a compound with a related structure but with a different orientation of the 
pyranone ring, was found to be ineffective as growth inhibitor even when tested at 
concentrations of 150 µM.  
The pyranoxanthenone 4 exhibited only a growth inhibitory effect against MCF-7 
cells being ineffective against SF-268 and NCI-H460 cell lines. This result is in 
agreement with that observed for xanthonolignoids [6, 17] where the equivalent 
angular xanthonolignoid revealed some selectivity to MCF-7 cells [6]. This 
different cell line response could reflect a possible tumour type-specific sensitivity 
of this compound for the breast cancer cell line. Compound 5 with the same 
functional groups, but a different orientation, showed a three fold decrease in its 
inhibitory activity against MCF-7 cell, but without the selectivity detected with 
compound 4.  
Although the number of the compounds tested is limited, some structural features 
important to the growth inhibitory effect can be inferred. Angular compounds 
showed in general higher activity (c.f. compound 2 in the three cell lines and 
compound 4 on MCF-7). It has been previously observed that angular compound 
1 [5] was active on these cell lines (Table 1).  
INSERT TABLE 1 
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2.3. Analysis of the molecular electrostatic potential superimposed onto total 
electron density (MEP/TED) and 3D-geometry 
All compounds possess close molecular volumes (Table 2). However, as observed 
in a previous study [5], the growth inhibitory activity presented by some of these 
compounds is due to the 3D-geometry and electronic density distribution. 
INSERT TABLE 2 
A simple inspection of the MEP/TED figures and structure of these compounds, 
Table 3, suggests that the compounds 4, 5 and 2 are expected to present 
antitumour activity, since they show similarities in 3D-geometry and charge 
distribution when compared with those observed for the compound ethyl 3-oxo-
3H-benzofuro[3,2-f]chromene-2-carboxylate (compound 1) [5]. However, it is 
compound 2 that shows the greatest ability to inhibit the in vitro growth of MCF-
7, NCI-H460 and SF-268 cell lines (Table 2), which is comparable to that 
observed before for compound 1 [5]. The charge distribution over the atoms of 
these molecules is surprisingly similar (Figure 1).  
INSERT FIG. 1 
The oxopyranoxanthenones, 4 and 5, present similar conformation, but they show 
specific variations in the charge distribution at some critical points. It was 
observed that compound 5 had only a slight inhibitory effect, while 4 showed a 
moderate growth inhibitory effect only against the MCF-7 cell line. This reflects 
the strict dependence between tumour type-specific sensitivity and a combination 
of 3D-geometry and a specific charge distribution (Figure 2).  
INSERT FIG. 2 
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These two compounds display a negative charge density localized in the internal 
part of the molecule, due to a carbonyl group (compound 4), and an oxygen atom 
from the xanthenone ring (compound 5). The local electronic effect caused by the 
carbonyl group in 4 seems to be responsible for its specificity to MCF-7 cell line. 
Despite this, the behaviour presented by compounds 4 and 5 suggests that a 
negative charge localized in this region is able to lower the tumour growth 
inhibitory activity. This is in agreement with the observations reported in a 
previous work, where the inhibitory activity of some benzopsoralens (including 
compound 1, [5]) was studied. A fifth interaction point must be introduced in the 
previously proposed model, involving the internal part of the condensed ring 
system of the bioactive compound and the bioreceptor. This point must be of 
major importance in the association bioactive compound/ bioreceptor, inducing 
the tumour growth inhibitory activity if the electronic density is positive, as it is 
the case for compounds 1 and 2.  
3. Conclusions 
The synthesis of five new analogues of benzopsoralens, derived from xanthen-9-
one and carbazole was described.  
Some of the compounds synthesized (4, 5, and 2) showed an interesting growth 
inhibitory effect against the MCF-7, SF-268 and NCI-H460 cell lines. All the 
compounds showing some biological activity (4, 5 and 2) have angular structures 
revealing the importance of the global molecular topology as previously observed 
for xanthonolignoids.  
Specific 3D-geometry and charge distribution are responsible for the biological 
activity displayed by some of these compounds. The behaviour presented by 
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compound 2, very similar to that presented by compound 1, and by compounds 4 
and 5 suggests that a fifth interaction point must be included in the previously 
proposed model [5], involving the internal part of the condensed ring of the 
bioactive compound and the bioreceptor(s). This seems to play a major role in the 
interaction between the bioactive compound and the bioreceptor(s).  
Experimental Part 
1. Chemistry 
General:  Light petroleum refers to solvent boiling in the range 40-60º. Column 
chromatography (CC) was performed on, silica gel 60 (70-230 mesh, Merck). 
Melting points were determined on a Gallenkamp apparatus and are uncorrected. 
UV spectra were recorded in EtOH on a SHIMADZU UV-2501 PC and data are 
presented in λmax (nm), (log ε [mol-1 dm3 cm-1]). IR were recorded on a Diffus-IR 
Bomem MB-Series FTIR spectrometer in cm-1. NMR spectra were obtained on a 
Varian Unity Plus at 300 MHz (1H) and 75.4 (13C) and the assignments were 
based on irradiation and 2D-NMR techniques (HMQC and HMBC), respectively. 
The solvent was CDCl3 (if not stated otherwise) and δ is in ppm, relative to 
internal SiMe4. Elemental analyses were carried out with a LECO CHNS-932. 
EIMS and HRMS spectra were carried out with an AutoSpecE spectrometer, in 
m/z (rel. %). 
General method of Duff formylation of hydroxyxanthen-9-ones:  To a soln. of 2-
hydroxyxanthen-9-one (212 mg, 1.00 mmol) in AcOH (99.8%, 15 ml), 
hexamethylenetetramine (HMTA) (475 mg, 3.39 mmol) was added and the 
mixture was refluxed for 4 h. After cooling a 10% soln. of HCl (30 ml) was added 
and the mixture was refluxed for 20 min. The mixture was then poured onto ice 
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(100 g) and extracted with Et2O (3 x 60 ml). The org. extracts were combined, 
dried (MgSO4) and the solvent partly removed. The reaction was followed by 
TLC (Et2O/petrol, 1:1). 
1-Hydroxy-9-oxoxanthene-2-carbaldehyde (8a). Yellow crystals (13%). M.p.: 
149-152º (EtOH). IR (Nujol): 1679 (C=O), 1645 (C=O), 1614, 1573, 1465, 1283, 
1255, 1063, 828, 769, 711, 639. 1H-NMR: 13.54 (s, OH); 10.62 (s, CHO); 8.34 
(dd, J = 7.8, 1.5, H-C(8)); 8.24 (d, J = 8.7, H-C(3)); 7.86 (ddd, J = 8.4, 7.5, 2.1, 
H-C(6)); 7.62 (br d, J = 8.4, H-C(5)); 7.51 (ddd, J = 8.0, 7.2, 1.2, H-C(7)); 6.91 
(d, J = 9.0, H-C(4)). EI-MS: 241 (13, [M+1]+), 240 (78, M+), 239 (100), 212 (16), 
183 (6), 155 (8), 127 (9), 92 (6). HR-EI-MS: 240.0415 (M+, C14H8O4; calc. 
240.0423). 
2-Hydroxy-9-oxoxanthene-1-carbaldehyde (8b). Product 8b precipitated as yellow 
crystals (135 mg, 56%). M.p.: 164-166º (EtOH) (lit. [8b] 163º (petrol)). IR 
(Nujol): 1640 (strong, C=O), 1465, 1330, 1304, 1233, 1211, 1152, 1057, 880, 
846, 817, 752. 1H-NMR: 13.02 (s, OH); 11.59 (s, CHO); 8.34 (dd, J = 7.8, 1.5, H-
C(8)); 7.78 (ddd, J = 7.8, 7.5, 1.5, H-C(6)); 7.75 (d, J = 9.6, H-C(4) or H-C(3)); 
7.53 (br d, J = 7.8, H-C(5)); 7.48-7.40 (m, 2H, H-C(7), and H-C(3) or H-C(4)). 
For other hydroxyxanthenones the reflux duration was variable and estimated by 
TLC (5 h, 2 h and 7 h, for 1, 3 and 4-hydroxyxanthen-9-one, resp.). It was 
necessary to use column chromatography or preparative chromatography to obtain 
1-hydroxy-9-oxoxanthene-2-carbaldehyde and 4-hydroxy-9-oxoxanthene-3-
carbaldehyde. All the aldehydes were obtained as yellow crystals. 
3-Hydroxy-9-oxoxanthene-4-carbaldehyde (8c). Yellow crystals (32%). M.p.: 
212-215º (EtOH) (lit. [18]: 223º (EtOH)). IR (Nujol): 1650 (strong, C=O), 1615, 
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1463, 1414, 1344, 1316, 1215, 1168, 1068, 819, 760, 735, 680. 1H-NMR: 12.66 
(s, OH); 10.74 (s, CHO); 8.48 (d, J = 9.0, H-C(1)); 8.36 (dd, J = 7.8, 1.8, H-C(8)); 
7.78 (ddd, J = 8.6, 7.5, 1.5, H-C(6)); 7.56 (br d, J = 8.4, H-C(5)); 7.47 (ddd, J = 
7.5, 6.6, 1.0, H-C(7)); 6.99 (d, J = 9.0, H-C(1)). MS-EI: 241 (16, [M+1] +), 240 
(100, M+), 239 (97), 222 (4), 194 (8), 155 (6), 127 (7), 92 (4), 69 (7). HR-EI-MS: 
240.0423 (M+, C14H8O4; calc. 240.0423). 
4-Hydroxy-3-oxoxanthene-3-carbaldehyde (8d). Yellow crystals (17%). M.p.: 
166-169º. IR (Nujol): 1667 (strong, C=O), 1632 (C=O), 1612, 1463, 1345, 1293, 
1234, 1216, 1297, 1019, 982, 904, 829, 806, 759, 743, 689. 1H-NMR: 11.70 (s, 
OH); 10.10 (s, CHO); 8.36 (dd, J = 7.8, 1.8, H-C(8)); 7.96 (d, J = 8.1, H-C(2) or 
H-C(1)); 7.82 (ddd, J = 8.7, 6.9, 1.5, H-C(6)); 7.68 (br d, J = 8.7, H-C(5)), 7.58 
(d, J = 8.4, H-C(1) or H-C(2)); 7.46 (ddd, J = 8.1, 6.9, 1.0, 1H, H-C(7)). MS-EI: 
241 (116, [M+1] +), 240 (100, M+), 239 (54), 222 (4), 194 (17), 183 (6), 155 (6), 
127 (6), 120 (6), 92 (3), 69 (3), 63 (3). HR-EI-MS: 240.0420 (M+, C14H8O4; calc. 
240.0423). 
General method of formation of the pyranone ring: To a soln. of 2-hydroxy-9-
oxoxanthene-1-carbaldehyde 8b (38 mg, 0.16 mmol) in EtOH (6 ml) diethyl 
malonate (35 mg, 0.22 mmol, previously dissolved in 1 ml EtOH), one drop of 
AcOH and one drop of piperidine were added and the mixture was refluxed for 
3.5 h. A precipitate formed on cooling and was filtered off and washed with cold 
EtOH.  
Ethyl 3,12-dioxopyran[3,2-a]xanthene-2-carboxylate (4). Compound 4 was 
obtained from 2-hydroxy-9-oxoxanthene-1-carbaldehyde 8b as a yellow solid (27 
mg, 50%. M.p.: 220-222º (CHCl3/petrol); UV (log ε, EtOH): 395 (3.94), 377 
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(3.99), 298 (4.22). IR (Nujol): 1769 (strong, C=O), 1641 (C=O), 1611, 1594, 
1562, 1466, 1327, 1249, 1227, 1207, 1119, 1035, 968, 900, 834, 799, 774, 725, 
684. 1H-NMR: 10.57 (s, H-C(1)); 8.34 (dd, J = 8.4, 1.7, H-C(11)); 7.84 (d, J = 
9.0, H-C(5) or H-C(6)); 7.82 (ddd, J = 8.4, 7.0, 1.7, H-C(9)); 7.73 (d, J = 9.0, H-
C(6) or H-C(5)); 7.58 (br d, J = 8.4, H-C(8)); 7.49 (ddd, J = 7.6, 7.0, 1.2, H-
C(10)); 4.48 (q, J = 7.5, Et), 1.47 (t, J = 7.2, Et). 13C-NMR: 177.76, 162.76, 
155.83, 155.04, 153.92, 152.26, 146.11 (CH), 135.39 (CH), 126.52 (CH), 124.94 
(CH), 124.90 (CH), 123.87 (CH), 122.19, 120.15, 117.76 (CH), 115.89, 115.72, 
62.05 (CH2), 14.24 (CH3). MS-EI: 337 (21), 336 (100, M+), 308 (9), 291 (66), 264 
(81), 236 (32), 223 (3), 212 (5), 207 (8), 179 (12), 150 (9). HR-EI-MS: 336.0635 
(M+, C19H12O6; calc. 336.0634). Anal. Calc. for C19H12O6.1/4(H2O): C 66.96, H 
3.70; found: C 67.01, H 3.71.  
Ethyl 3,7-dioxopyran[2,3-c]xanthene-2-carboxylate (5). Compound 5 was 
obtained from 3-hydroxy-9-oxoxanthene-4-carbaldehyde 8c as yellow crystals (26 
mg, 55%). M.p.: 196-197º (EtOH). UV (log ε, EtOH): 350 (4.04), 328 (4.13), 307 
(4.08), 276 (4.38). ΙR (Nujol): 1771 (strong, C=O), 1660 (C=O), 1624, 1463, 1262, 
1232, 1083, 1019, 965, 793, 773, 722, 630. 1H-NMR: 9.21 (s, H-C(1)); 8.59 (d, J = 
9.0, H-C(6)); 8.39 (dd, J = 7.8, 1.5, H-C(8)); 7.84 (ddd, J = 8.7, 7.2, 1.5, H-C(10)); 
7.67 (br d, J = 8.4, H-C(11)); 7.51 (ddd, J = 7.7, 7.2, 1.2, H-C(9)); 7.36 (d, J = 9.0, 
H-C(5)); 4.50 (q, J = 6.9, Et); 1.48 (t, J = 7.2, Et). 13C-NMR: 175.25 (C(7)), 
162.94 (CO2Et), 159.41 (C(4a)), 155.65 (C(11a)), 155.52 (C(3)), 153.31 (C(12a)), 
142.22 (C(1)), 135.37 (C(10)), 132.74 (C(6)), 126.97 (C(8)), 125.34 (C(9)), 121.88 
(C(7a)), 118.06 (C(12b) ou C(2)), 117.95 (C(11)), 117.93 (C(12b) or C(2)), 113.29 
(C(5)), 108.083 (C(6a)), 62.43 (CH2), 14.26 (CH3). MS-EI): 337 (18, [M+1] +), 
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336 (83, M+), 308 (4), 291 (85), 264 (100), 236 (28), 207 (24), 179 (8), 150 (8), 87 
(6), 75 (4). HR-EI-MS: 336.0639 (M+, C19H12O6; calc. 336.0634).  
Synthesis of pyranoxanthen-9-one (6) via xanthene 
3-Methoxyxanthene. The 3-methoxyxanthen-9-one was reduced with LiAlH4 in 
dry Et2O giving an oil which was purified by column chromatography (TLC 
control: Et2O/petrol, 3:7). The product was obtained as colourless crystals 
(Et2O/petrol, 5:95) (77%). M.p.: 78-82º (CH2Cl2/petrol) (lit. [19]: 79-80º 
(hexane)). IR (KBr): 3059, 2996, 2840, 1604, 1577, 1486, 1444, 1314, 1237, 
1150, 1093, 963, 836, 760. 1H-RMN (acetone-d6): 7.28-7.19 (m, H-C(8) and H-
C(6)), 7.15 (br d, J = 8.3, H-C(1)), 7.09-7.01 (m, H-C(5) and H-C(7)), 6.67 (dd, J 
= 8.3, 2.5, H-C(2)), 6.62 (d, J = 2.5, H-C(4)), 4.00 (s, CH2), 3.81 (s, OMe). 
3-Methoxyxanthene-2-carbaldehyde (9a). Vilsmeier formylation of 3-
methoxyxanthene with N-methylformanilide and POCl3 in CH2Cl2 (9 h reflux) 
gave an oil which was purified by column chromatography. The starting 3-
methoxyxanthene was partly recovered (20 mg, 31%) and the title compound was 
obtained as light yellow crystals (22 mg, 31%). M.p.: 156-158º (lit. [12a]: 154º). 
IR (KBr): 1671 (C=O), 1628, 1609, 1572, 1505, 1468, 1445, 1426, 1405, 1330, 
1307, 1290, 1235, 1185, 1113, 1015, 963, 894, 830, 773, 753. 1H-NMR: 10.34 (s, 
CHO), 7.77 (s, H-C(1)), 7.25-7.18 (m, H-C(6) and H-C(8)), 7.11-7.03 (m, H-C(7) 
and H-C(5)), 6.64 (s, H-C(4)), 4.01 (s, CH2), 3.93 (s, OMe). 
3-Hydroxyxanthene-2-carbaldehyde (9b). The 3-methoxyxanthene-2-
carbaldehyde 9a was demethylated with BBr3 in dry CH2Cl2 at low temperature 
(dry ice/acetone) to give compound 9b as a light yellow solid (67 mg, 100%). 
M.p.: 172-174º (lit. [12a] 159º). IR (Nujol): 1664 (strong, C=O), 1619, 1593, 
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1570, 1293, 1245, 1186, 1148, 968, 880, 869, 759, 726. 1H-NMR: 11.15 (s, OH), 
9.78 (s, CHO), 7.37 (br s, H-C(1)), 7.28-7.16 (m, H-C(6) and H-C(8)), 7.12-7.06 
(m, H-C(5) and H-C(7)), 6.64 (s, H-C(4)), 4.04 (s, CH2).  
Ethyl 2-oxopyran[3,2-b]xanthene-3-carboxylate (10). This compound was 
obtained by the general method already described (4.2), as beige thin needles (78 
mg, 73%) M.p.: 240-242º (EtOH), IR (Nujol): 1769 (C=O), 1752 (C=O), 1632, 
1615, 1564, 1456, 1303, 1295, 1275, 1233, 1195, 1136, 1033, 991, 907, 847, 797, 
750, 731, 666. 1H-NMR: 8.49 (s, H-C(4)), 7.43 (s, H-C(5)), 7.30-7.20 and 7.15-
7.08 (m, H-C(7), H-C(8), H-C(9) and H-C(10)), 7.03 (s, H-C(12)), 4.42 (q, J = 6.9, 
Et), 4.13 (s, CH2), 1.42 (t, J = 7.2, Et). 13C-NMR: 163.53, 157.13, 157.09, 155.61, 
150.89, 148.56 (CH), 129.98 (CH), 129.20 (CH), 128.48 (CH), 124.48 (CH), 
119.53, 118.93, 116.95 (CH), 115.70, 114.02, 104.42 (CH), 62.07, 27.23, 14.53. 
MS-EI: 323 (20, [M+1] +), 322 (100, M+), 321 (73), 293 (13), 277 (23), 250 (17), 
221 (17), 193 (8), 163 (6), 138 (8). HR-EI-MS: 322.0845 (M+, C19H14O5; calc. 
322.0841).  
Ethyl 2,6-dioxopyran[3,2-b]xanthene-3-carboxylate (6). To a soln. of the 
pyranoxanthene 10 (32 mg, 0.10 mmol) in pyridine (5 ml) powdered chromium 
(VI) oxide (40 mg, 0.40 mmol) was added and the mixture was left stirring at 
room temperature for 2.5 h. The mixture became dark brown and a solid 
precipitated. The mixture was poured over HCl 2 M (30 ml) and was extracted 
with CHCl3 (3x 30 ml) and EtOAc (4 x 30 ml). The extracts were combined, dried 
and the solvent was evaporated. The resulting solid was crystallized from a 
mixture of CHCl3 and MeOH. The chromatographic control (TLC) was done using 
CHCl3/MeOH, (99:1). The title compound was obtained as a white powder (28 
 15 
mg, 83%). M.p.: 305-307º (CHCl3/CH3OH), decomposes above 300º. UV (log ε, 
EtOH): 360 (3.80), 267 (4.46). IR (Nujol): 1768 (C=O), 1652 (C=O), 1623, 1607, 
1561, 1465, 1352, 1222, 1139, 1027, 973, 846, 795, 762, 692. 1H-NMR (CDCl3 + 
CD3OD): 8.64 (s, H-C(4) or H-C(5)), 8.62 (s, H-C(4) or H-C(5)), 8.29 (dd, J = 8.1, 
1.8, H-C(7)), 7.77 (ddd, J = 8.4, 7.2, 1.8, H-C(9)), 7.50 (br d, J = 8.4, H-C(10)), 
7.42 (ddd, J = 7.9, 6.9, 1.2, H-C(8)), (s, H-C(12)), 4.38 (q, J = 6.9, Et), 1.38 (t, J = 
7.2, Et). 13C-NMR, δ (CDCl3 + CD3OD): 148.23 (CH), 135.80 (CH), 130.08 (CH), 
126.68, 124.97 (CH), 118.02 (CH), 105.07 (CH), 62.13 (CH2), 13.95 (CH3). The 
signals described correspond to carbon atoms either than quaternary, due to the 
low solubility of the compound. MS-EI: 337 (21, [M+1] +), 336 (98, M+), 308 (4), 
291 (100), 264 (93), 236 (24), 207 (18), 179 (8), 150 (6), 145 (5). HR-EI-MS: 
336.0633 (M+, C19H12O6; calc. 336.0634). Anal. calc. for C19H12O6: C 67.86, H 
3.60; found: C 67.43, H 3.71.  
Synthesis of the pyranocarbazoles 
Reimer-Tiemann formylation. 2-Hydroxycarbazole (2 g, 11 mmol), was treated 
with CHCl3 and NaOH and gave, after column chromatography (Et2O/petrol, 1:9), 
2-hydroxycarbazole-1-carbaldehyde 11b as yellow crystals, (0.46 g, 20%). M.p.: 
219-220º (decomposes above 200º) (lit. [12c]: 232º (EtOH)). IR (Nujol): 3405 
(NH), 1633 (C=O), 1598, 1318, 1278, 1206, 1170, 1115, 1085, 1032, 938, 784, 
775, 757, 743, 722. 1H-NMR (acetone-d6): 11.16 (br s, OH), 10.69 (s, CHO), 
10.33 (br s, NH), 8.27 (d, J  = 8.1, H-C(4)), 8.06 (br d, J  = 8.1, H-C(5)), 7.71 (br 
d, J  = 8.1, H-C(8)), 7.39 (ddd, J = 7.9, 7.5, 1.5, H-C(7)), 7.25 (ddd, J = 7.9, 6.9, 
1.0, H-C(6)), 6.85 (d, J = 8.4, H-C(3)). 
Formylation via carbamate formation 
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i) Synthesis of the carbamate. A soln. of the 2-hydroxycarbazole (0.45 g, 5 mmol) 
in dry pyridine (2 ml) and N,N-diethylcarbamoyl chloride (0.745 g, 11 mmol) was 
heated for 4 h at 100°. The mixture was poured onto crushed ice (75 g) and 
extracted with Et2O (3x 25 ml) and the org. extract was washed with 2 M NaOH 
(3x 25 ml) and H2O (3x 25 ml) and dried (MgSO4). After solvent evaporation the 
corresponding (N,N-diethylcarbamoyl)-carbazole was obtained as a brown oil. 
The carbamate was used without further purification. 
2-(N,N-Diethylcarbamoyl)-carbazole (11a). Light brown oil (0.634 g, 92%), 
which was used without purification. IR (film): 3408, 3307 (NH), 2975, 2934, 
1700 (strong, C=O), 1633, 1611, 1461, 1422, 1380, 1326, 1271, 1230, 1166, 
1119, 1002, 971, 865, 748, 727, 666. 1H-NMR: 8.26 (br s, NH), 7.94 (br d, J = 
7.8, H-C(5)), 7.89 (d, J = 8.4, H-C(4)), 7.40-7.33 (m, H-C(7) and H-C(8)), 7.24-
7.18 (m, H-C(6)), 7.20 (d, J = 2.1, H-C(1)), 6.95 (dd, J = 8.4, 2.1, H-C(3)), 3.60-
3.40 (m, Et), 1.40-1.20 (m, Et). 
ii) Formylation of the carbamate. A soln. of sec-BuLi (6.75 ml of a 0.13 M soln. 
in cyclohexane, 1.3 mmol) was added under N2 to a stirred mixture of TMEDA 
(0.783 g, 6.7 mmol) in dry THF at –78º. After 5 min. a soln. of the carbamate 11a 
(0.634 g, 2.25 mmol) in dry THF (6 ml) was added. After 60 min. DMF (0.7 ml) 
was added, the mixture was left for 2 h while it reached room temperature and 
then it was left stirring for 48 h. During this period the solution changed from 
yellow to brown. A saturated soln. of ammonium chloride (75 ml) was added and 
the mixture was extracted with chloroform (3 x 20 ml). The combined org. 
extracts were dried (MgSO4) and the solvent was removed under reduced 
pressure, giving a mixture of compounds as a brown oil. This mixture was 
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submitted to column chromatography (silica, ethyl EtOAc/light petroleum 
mixtures of increasing polarity).  The main product isolated was the 2-
hydroxycarbazole-3-carbaldehyde 11c as an off-white solid (150 mg, 32%). M.p.: 
232-233º (decomposes above 200º) (lit. [12c] 240º (EtOH)). IR (Nujol): 3371 
(NH), 1704, 1644 (strong, C=O), 1326, 1250, 1205, 1167, 1015, 896, 871, 855, 
822, 772, 721.1H-NMR: 11.51 (s, OH), 10.77 (br s, NH), 10.04 (s, CHO), 8.51 (s, 
H-C(4)), 8.13 (br d, J = 7.5, H-C(5)), 7.54 (br d, J = 8.1, H-C(8)), 7.43 (ddd, J = 
8.1, 7.2, 1.2, H-C(7)), 7.27 (ddd, J = 8.1, 7.2, 0.9, H-C(6)), 6.94 (s, H-C(1)). 
iii) Formation of the pyranone ring 
Ethyl 3-oxopyran[3,2-a]carbazole-2-carboxylate (2) was obtained, as described 
above, from 1-formyl-2-hydroxycarbazole 11b (together with starting material, 
17%) as a yellow solid after recrystallisation from CHCl3 /cyclohexane (24 mg, 
68%). M.p.: 211-212º (decomp.). UV (log ε, EtOH): 394 (4.39), 320 (4.40), 286 
(4.40). IR (Nujol): 3341 (NH), 1746 (strong, C=O), 1614, 1345, 1330, 1257, 
1217, 1193, 1117, 1089, 1034, 798, 776, 739, 666. 1H-NMR (acetone-d6): 11.49 
(br s, NH), 9.25 (br s, H-(1)), 8.50 (br d, J = 8.7, H-C(6)), 8.18 (br d, J = 8.1, H-
C(7)), 7.64 (br d, J = 8.1, H-C(10)), 7.48 (ddd, J = 8.1, 7.2, 1.2, H-C(9)), 7.32 
(ddd, J = 7.4, 7.2, 0.9, H-C(8)), 7.22 (br d, J = 8.7, H-C(5)), 4.40 (q, J = 6.9, Et), 
1.41 (t, J = 7.2, Et). 13C-NMR (acetone-d6): 164.00 (CO2Et), 156.88 (C=O), 
155.55 (C(4a)), 144.73 (C(1)), 140.97 (C(10a)), 137.88 (C(11a)), 127.53 (C(6)), 
126.63 (C(9)), 123.51 (C(7a)), 121.22 (C(8)), 120.77 (C(7)), 120.21 (C(6a)), 
116.57 (C(2)), 112.26 (C(10)), 108.27 (C(5)), 104.39 (C(11b)), 61.89 (CH2), 
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14.56 (CH3). MS-EI: 308 (20, [M+1]+), 307 (100, M+), 262 (19), 235 (33), 207 
(11), 178 (17). HR-EI-MS: 307.0840 (M+, C18H13NO4; calc. 307.0845).  
Ethyl 3-oxopyran[2,3-b]carbazole-2-carboxylate (3). Compound 3 was obtained, 
as described above, from 3-formyl-2-hydroxycarbazole 11c, together with starting 
material (27%), as a yellow solid (31 mg, 20%). M.p.: 335-336º (decomp.). UV 
(log ε, EtOH): 370 (4.49), 305 (4.89), 275 (5.08). IR (Nujol): 3271 (NH), 1765 
(C=O), 1746 (C=O), 1636, 1596, 1569, 1276, 1241, 1200, 1044, 1016, 795, 725, 
665. 1H-NMR  (DMSO-d6): 11.91 (br s, NH), 8.88 (s, H-C(1)), 8.67 (s, H-C(11)), 
8.13 (br d, J = 7.8, H-C(10)), 7.55 (br d, J = 7.8, H-C(7)), 7.46 (br t, J = 8.1, H-
C(8)), 7.41 (s, H-C(5)), 7.27 (br t, J = 7.5, H-C(9)), 4.28 (q, J = 7.2, Et), (t, J = 6.9,  
Et). 13C-NMR (DMSO-d6): 163.11 (CO2Et), 156.74 (C=O), 153.75 (C(4a)), 150.59 
(C(1)), 144.04 (C(5a)), 141.01 (C(6a)), 126.89 (C(7)), 122.76 (C(10)), 121.91 
(C(10a)), 121.16 (C(10b)), 120.60 (C(10)), 120.32 (C(9)), 112.08 (C(2)), 111.59 
(C(7)), 110.73 (C(11a)), 96.83 (C(5)), 60.88 (CH2), 14.20 (CH3). MS-EI: 308 (20, 
[M+1]+), 307 (100, M+), 262 (45), 235 (41), 207 (25), 178 (25), 89 (12), 69 (51). 
HR-EI-MS: 307.0848 (M+, C18H13O4N; calc. 307.0845).  
2. Tumour cell growth assay:  The effects of compounds on the growth of tumour 
cell lines MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung 
cancer) and SF-268 (CNS cancer) were evaluated according to the procedure 
adopted by the National Cancer Institute (NCI, USA) for in vitro anticancer drug 
screening using the protein-binding dye sulforhodamine B (SRB) to assess growth 
inhibition [20, 21]. Cells were routinely maintained as adherent cell cultures in 
RPMI-1640 medium supplemented with 5% heat-inactivated fetal bovine serum, 2 
mM glutamine and 50 µg/mL of gentamicin at 37º in an humidified atmosphere 
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containing 5% CO2. The optimal plating density of each cell line, that ensure 
exponential growth throughout all the experimental period, was the same as 
originally published [20] and was respectively 7.5x104 cells/mL to NCI-H460, 
1.5x10
5
 cells/mL to MCF-7 and SF-268. Cells were exposed for 48 h to five 
concentrations of compounds starting from a maximum concentration of 150 µM.  
Compounds, prepared in DMSO, were freshly diluted with cell culture medium 
immediately prior the assays. Final concentrations of DMSO (≤ 0.25%) did not 
interfere with the cell lines growth. For each test compound and for each cell line 
a dose-response curve was generated and the growth inhibition of 50% (GI50), 
corresponding to the concentration of compound that inhibits 50% of the net cell 
growth was determined as described [20]. Doxorubicin, used as a positive control, 
was tested in the same manner. 
 
3. Theoretical calculations:  The structure of the isolated molecules was initially 
optimized using the semi-empirical method PM3 [22]. Subsequentely, these 
structures were refined using the Density Functional Theory (DFT) [23]. The 
B3LYP hybrid functional and 6-31G* basis sets was used.  
In the DFT optimizations, the Berny gradient was used. The requested 
convergence limit on RMS density matrix was 1 x 10-8 and the threshold values 
for the maximum force and the maximum displacement were 0.000450 and 
0.001800 a.u. respectively. 
The visualization of the structures was performed with GaussView 3 [24]. The 
molecular volumes were calculated using the facilities of Hyperchem 5.11 [25].  
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Table 1.    Effect of compounds on the growth of human tumour cell lines 
 
 
 
 
 
 
 
 
GI50 (µM) 
Compounds MCF-7 SF-268 NCI-H460 
1 13.9±1.2 20.4±1.1 17.6±1.4 [5] 
4 48.2 ± 3.4 ≥ 150 ≥ 150 
5 138.8 ± 4.8 142.7 ± 5.9 145.7 ± 2.9 
6 > 150 > 150 > 150 
2 11.6 ± 0.5 35.9 ± 3.9 20.6 ± 1.5 
3 > 150 > 150 > 150 
Results are mean ± SEM of 1-6 independent experiments performed in 
duplicate. Doxorubicin was used as positive control: GI50 (MCF-7) = 42.8 
± 8.2 nM; GI50 (SF-268) = 93.0 ± 7.0 nM;  GI50 (NCI-H460) = 94.0 ± 
8.7 nM. 
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Scheme 1 Duff formylation of hydroxyxanthen-9-ones 7. Reaction conditions:  i) HMTA/ CH3CO2H/ reflux. 
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Scheme 2  Formation of the pyranone ring. i) CH2(CO2Et)2, EtOH, piperidine, AcOH, reflux. 
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Scheme 3 Synthesis of the 2-formyl-3-hydroxyxanthene 9b and pyranoxanthen-9-one 6. Reaction conditions: i) 1. LiAlH4, 
Et2O, 1 h reflux. 2. NH4Cl. ii) POCl3, N-methyl formanilide, CH2Cl2, reflux, 9 h. iii) 1. BBr3, CH2Cl2. 2. H2O. iv) 
CH2(CO2Et)2 /EtOH, 3 hrs. v) CrO3/pyridine, 2.5 hrs. 
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Scheme 4 i) NaOH/CHCl3. ii) ClCONEt2/pyridine. iii) 1. sec-BuLi, TMEDA, THF, -78°C; 2. DMF, -78 ºC-25 ºC. 
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Figure 1 and 2 in separated files 
Figure 1  Charge distribution for compounds 1 and 2 
 
Figure 2  Charge distribution for compounds 4 and 5 
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